S. Kelly

Statistics

Publications

Citations

549

H-Index

Active since

2008

Affiliations

Bristol-Myers Squibb (United States)(Current)

S. Kelly is an author at Bristol-Myers Squibb (United States) specializing in pharmacotherapy, autoimmune rheumatic diseases, and clinical pharmacology.

Publications per year

2008–2010

Publications

The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial

Joan T. Merrill, Rubén Burgos‐Vargas, René Westhovens et al. · Arthritis & Rheumatism · 2010 · 375 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

Michael Schiff, C Pritchard, J. Eugene Huffstutter et al. · Annals of the Rheumatic Diseases · 2008 · 154 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study

JT Merrill, Rubén Burgos‐Vargas, René Westhovens et al. · Queensland's institutional digital repository (The University of Queensland) · 2008 · 20 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +3

1–3 of 3